Zegerid Switch Progress Generates Bottom Line Help For Santarus

Santarus' OTC licensing of its Zegerid Rx heartburn remedy to Schering-Plough has yet to pay dividends for S-P, but the deal is already helping Santarus reduce its net loss

More from Archive

More from Pink Sheet